Transforming Community-Based Healthcare

Corporate Presentation

September 2021



Disclaimer

This presentation (together with oral statements made in connection herewith, this "Presentation") is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination between LumiraDx Limited ("LumiraDx") and CA Healthcare Acquisition Corp. ("CAH") and related transactions (the "Proposed Business Combination") and for no other purpose. By accepting this Presentation, you acknowledge and agree that you will not distribute, disclose or use such information in any way detrimental to LumiraDx or CAH.

No representations or warranties, express or implied are given in, or in respect of, this Presentation. You are also being advised that the United States securities laws restrict persons with material non-public information about a company obtained directly or indirectly from that company from purchasing or selling securities of such company, or from communicating such information to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell such securities on the basis of such information. To the fullest extent permitted by law, in no circumstances will CAH, LumiraDx or any of their respective subsidiaries, stockholders, affiliates, representatives, partners, directors, officers, employees, advisers or agents be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from the use of this Presentation, its contents, its omissions, reliance on the information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith. In addition, this Presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of LumiraDx or the Proposed Business Combination. Viewers of this Presentation should each make their own evaluation of LumiraDx and of the relevance and adequacy of the information and should make such other investigations as they deem necessary.

Nothing herein should be construed as legal, financial, tax or other advice. You should consult your own advisers concerning any legal, financial, tax or other considerations concerning the opportunity described herein. The general explanations included in this Presentation cannot address, and are not intended to address, your specific investment objectives, financial situations or financial needs.

The Proposed Business Combination will be submitted to the stockholders of CAH for their consideration and approval at a special meeting of stockholders. LumiraDx filed a registration statement on Form F-4 (the "Registration Statement") with the SEC on July 7, 2021 (File No. 333-257745), which includes preliminary and definitive proxy statements and be distributed to holders of CAH's common stock in connection with CAH's solicitation for proxies for the vote by CAH's stockholders in connection with the Proposed Business Combination and other matters as described in the Registration Statement, as well as the prospectus relating to the offer of the securities to the issued to CAH's shareholders in connection with the completion of the business combination. After the Registration Statement has been declared effective, CAH will mail a definitive proxy statement and other relevant documents to its stockholders as of the record date established for voting on the Proposed Business Combination. CAH's stockholders and other interested parties are advised to read, once available, the preliminary proxy statement and any amendments thereto and, once available, the definitive proxy statement / prospectus, in connection with CAH's solicitation of proxies for its special meeting of stockholders to be held to approve, among other things, the Proposed Business Combination, because these documents will contain important information about CAH, LumiraDx and the Proposed Business Combination. Stockholders may also obtain a copy of the preliminary or definitive proxy statement / prospectus, once available, as well as other documents filed with the SEC regarding the Proposed Business Combination and other documents filed with the SEC by CAH, without charge, at the SEC's website located at www.sec.gov or by directing a request to 99 Summer Street, Suite 200, Boston, MA 02110, Attention: Larry Neiterman (larry@cahcspac.com). This Presentation does not constitute a solicitation of any proxy.

PARTICIPANTS IN THE SOLICITATION

CAH and its directors and executive officers and other persons may be deemed to be participants in the solicitations of proxies from CAH's stockholders in respect of the Proposed Business Combination and the other matters set forth in the definitive proxy statement / prospectus. Information regarding CAH's directors and executive officers is available under the heading "Management" in CAH's final prospectus dated January 26, 2021. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement / prospectus relating to the Proposed Business Combination when it becomes available. Stockholders, potential investors and other interested persons should read the proxy statement / prospectus carefully when it becomes available.

NO OFFER OR SOLICITATION

This Presentation does not constitute an offer, or a solicitation of an offer, to buy or sell any securities, investment or other specific product, or a solicitation of any vote or approval, nor shall there be any sale of securities, investment or other specific product in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any offering of securities (the "Securities") will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), and will be offered as a private placement to a limited number of institutional "accredited investors" as defined in Rule 501(a)(1), (2), (3) or (7) under the Securities Act and "Institutional Accounts" as defined in FINRA Rule 4512(c). Accordingly, the Securities must continue to be held unless a subsequent disposition is exempt from the registration requirements of the Securities Act. Investors should consult with their counsel as to the applicable requirements for a purchaser to avail itself of any exemption under the Securities Act. The transfer of the Securities may also be subject to conditions set forth in an agreement under which they are to be issued. Investors should be aware that they might be required to bear the final risk of their investment for an indefinite period of time. Neither LumiraDx nor CAH is making an offer of the Securities in any jurisdiction where the offer is not permitted.

NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS PRESENTATION IS TRUTHFUL OR COMPLETE.

FORWARD-LOOKING STATEMENTS

All statements other than statements of historical facts contained in this Presentation are forward-looking statements. Forward-looking statements may generally be identified by the use of words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "project," "forecast," "predict," "potential," "seem," "seek," "future," "outlook," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other financial and performance metrics, projections of market opportunity and market share. These statements are based on various assumptions, whether or not identified in this Presentation, and on the current expectations of LumiraDx's and CAH's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions, and such differences may be material. Many actual events and circumstances are beyond the control of LumiraDx and CAH. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; risks relating to the uncertainty of the projected financial information with respect to LumiraDx; the inability of the parties to successfully or timely consummate the Proposed Business Combination, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the Proposed Business Combination or the expected benefits of the Proposed Business Combination or that the approval of the stockholders of CAH or LumiraDx is not obtained; the failure to realize the anticipated benefits of the Proposed Business Combination; risks relating to the uncertainty of the projected financial information with respect to LumiraDx; risks related to the rollout of LumiraDx's business and the timing of expected business milestones; the effects of competition on LumiraDx's future business; the amount of redemption requests made by CAH's public stockholders; the ability of CAH or LumiraDx to issue equity or equity-linked securities or obtain debt financing in connection with the Proposed Business Combination or in the future and those factors discussed in CAH's final prospectus dated January 26, 2021 and any Quarterly Report on Form 10-Q, in each case, under the heading "Risk Factors," and other documents of CAH or LumiraDx filed, or to be filed, with the SEC. If any of these risks materialize or CAH's or LumiraDx's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither CAH nor LumiraDx presently know or that CAH and LumiraDx currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect CAH's and LumiraDx's expectations, plans or forecasts of future events and views as of the date of this Presentation. CAH and LumiraDx anticipate that subsequent events and developments will cause CAH's and LumiraDx's assessments to change. However, while CAH and LumiraDx may elect to update these forward-looking statements at some point in the future, CAH and LumiraDx specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing CAH's and LumiraDx's assessments as of any date subsequent to the date of this Presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements. Neither LumiraDx, CAH, nor any of their respective affiliates have any obligation to update this Presentation.

INDUSTRY AND MARKET DATA

This presentation includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market opportunities. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. CAH and LumiraDx believe that these third-party sources and estimates are reliable, but have not independently verified them. LumiraDx's estimates of the potential market opportunities for its Platform include several key assumptions based on industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While LumiraDx and CAH believe that their own internal assumptions are reasonable, no independent source has verified such assumptions. The industry in which LumiraDx operates is subject to a high degree of uncertainty and risk due to a variety of important factors that could cause results to differ materially from those expressed in the estimates made by third parties and by LumiraDx or CAH.

USE OF PROJECTIONS

This Presentation contains projected financial information with respect to LumiraDx, including, but not limited to, estimated results for fiscal year 2021. Such projected financial information constitutes forward-looking information, and is for illustrative purposes only and should not be relied upon as necessarily being indicative of future results. The assumptions and estimates underlying such financial forecast information are inherently uncertain and are subject to a wide variety of significant business, economic, competitive and other risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. See "Forward-Looking Statements" paragraph above. Actual results may differ materially from the results contemplated by the financial forecast information contained in this Presentation, and the inclusion of such information in this Presentation should not be regarded as a representation by any person that the results reflected in such forecasts will be achieved. Neither CAH's nor LumiraDx's independent auditors have audited, reviewed, compiled or performed any procedures with respect to the projections for the purpose of their inclusion in this Presentation, and accordingly, neither of them expressed an opinion or provided any other form of assurance with respect thereto for the purpose of this Presentation.

FINANCIAL INFORMATION; NON-GAAP FINANCIAL MEASURES

Some of the financial information and data contained in this Presentation is unaudited and does not conform to Regulation S-X promulgated under the Securities Act. Accordingly, such information and data may not be included in, may be adjusted in or may be presented differently in, any proxy statement/prospectus or registration statement to be filed by CAH with the SEC. Some of the financial information and data contained in this Presentation, have not been prepared in accordance with United States generally accepted accounting principles ("GAAP"). CAH and LumiraDx believe these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to LumiraDx's financial condition and results of operations. LumiraDx's management uses these non-GAAP measures for trend analyses, for purposes of determining management incentive compensation and for budgeting and planning purposes. CAH and LumiraDx believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating projected operating results and trends in and in comparing LumiraDx's financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. The principal limitation of these non-GAAP financial measures is that they are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures.

TRADEMARKS AND TRADE NAMES

LumiraDx and CAH own or have rights to various trademarks, service marks and trade names that they use in connection with the operation of their respective businesses. This Presentation also contains trademarks, service marks and trade names of third parties, which are the property of their respective owners. The use or display of third parties' trademarks, service marks, trade names or products in this Presentation is not intended to, and does not imply, a relationship with LumiraDx or CAH, or an endorsement or sponsorship by or of LumiraDx or CAH. Solely for convenience, the trademarks, service marks and trade names referred to in this Presentation may appear with the ®, TM or SM symbols, but such references are not intended to indicate, in any way, that LumiraDx or CAH will not assert, to the fullest extent under applicable law, their rights or the right of the applicable licensor to these trademarks, service marks and trade names.

Transaction Details

Revised Transaction Overview

Revised transaction terms adjust LumiraDx's pro forma valuation for the combined group from $5 billion to $3 billion (excluding $115 million raised by CAHC in its IPO).

- **Attractive Entry Point -** Terms establish a more attractive entry point for investors, and a highly compelling investment thesis on an absolute and relative basis
- **Revised Deal Factors -** Factors considered in revising the valuation include: the recent market environment for publicly traded diagnostic companies, volatility in COVID-19 testing demand, and feedback from CAHC's advisors and shareholders
- **LumiraDx Roadmap -** LumiraDx has a roadmap of 10 new test approvals over the next 24 months on its platform, including Troponin, Flu/COVID, and TB.
- **Updated Guidance -** LumiraDx recently updated 2021 revenue guidance range to $300-500 million and provided 2024 revenue guidance in the range of $1.00-1.25 billion.
- **Closing -** The Boards of Directors of both LumiraDx and CAHC reaffirm their recommendation of the deal, which is expected to close in the fall of this year, subject to approval by the security holders of CAHC and LumiraDx and the satisfaction of customary closing conditions. Upon closing, LumiraDx is expected to trade on Nasdaq under the ticker symbol "LMDX."

Pro-Forma Terms of Revised Deal (Based on 6/30)

(Stated in Millions other than per share and percentage metrics)

Pro Forma Ownership



Key Points

- No existing LumiraDx shareholders will be selling shares
- The additional capital and cash from operations will provide growth capital to support increasing product demand, continued R&D activities and commercial and manufacturing expansion.
- The transaction is currently expected to close in the fall of 2021.

Sources and Uses

Sources	
LumiraDx Equity	$3,000
CAHC Cash Held in Trust[1]	$115
Total Sources	**$3,115**
Uses	
LumiraDx Equity	$3,000
Cash to LumiraDx Balance Sheet	$99
Estimated Combined Fees & Expenses	$16
Total Uses	**$3,115**

Pro Forma Valuation

Shares Outstanding	315
Price Per Share	$10.00
Market Capitalization	$3,148
Less Cash Balance[2]	$(344)
Plus Debt[3]	$318
Enterprise Value	**$3,122**

(1) Assumes no redemptions
(2) Assumes company cash balance as of 6/30/2021 of $245M plus $115M from cash in trust minus $16M of estimated combined fees & expenses
(3) Includes $300M of BioPharma Credit debt, $18M The Gates Foundation debt, and excludes convertible debt that will be converted as a part of the transaction
Note 1: Numbers presented are pro forma, estimated as of 6/30/2021, and exclude any funding from Capital One
Note 2: Excludes 5.75M public warrants

LumiraDx's Proven Track Record

Ron Zwanziger
CEO, Co-Founder, Chairman and Director

Dave Scott, Ph.D.
Chief Technology Officer, Co-Founder and Director

Jerry McAleer, Ph.D.
Chief Scientist, Co-Founder and Director

David Walton, D.M.S.
Chief Commercial Officer

Nigel Lindner, Ph.D.
Chief Innovation Officer

Veronique Ameye
Executive Vice President and General Counsel

Tom Quinlan
General Manager, Health IT

Dorian LeBlanc, C.P.A.
CFO and Vice President, Global Operations

Peter Scheu
President, North American Commercial Operations

Pooja Pathak
Vice President, Platform Strategy

lumiraDx™

Founded in 2014

ALERE

Sold to Abbott for $8.2B

INVERNESS

Sold to J&J for $1.3B



MEDISENSE

Sold to Abbott for $900M

lumiraDx™

Our Mission

We are focused on transforming community-based healthcare by providing fast, accurate and comprehensive diagnostic information to healthcare providers at the point of need, thereby enabling better medical decisions leading to improved outcomes at lower cost.

Our diagnostic solutions are designed to be affordable and accessible for every individual around the world.

Current Point of Care (POC) Solutions Have Major Limitations

The traditional approach to POC test development has limited scalability and has resulted in ineffective, inefficient and costly solutions

TNI, CK-MB, Myoglobin, BNP, D-Dimer, TOX

Flu A/B, RSV, Strep

Flu A/B, RSV, Strep

Lipid Profile, Glucose

INR

HbA1c, CRP, ACR

- **Poor clinical performance in areas of high clinical need**
- **Limited test menu**
- **High cost of total ownership**

lumiraDx™

We Have Developed and Commercialized an Innovative, Disruptive Solution for POC Testing

Consolidating multiple POC systems onto a single instrument, The LumiraDx Platform is designed to be a one-stop solution to transform diagnostic testing and health outcomes around the world



- **Lab-comparable performance in minutes**
- **Broad menu of tests on a single instrument**
- **Low cost of ownership**

lumiraDx™

Bill Gates Video

Business Momentum: COVID-19 Deployment A Was A Major Accelerator of Our Plans



Key Takeaways

World-Class Diagnostics Management Team
Experienced team of diagnostics industry professionals with a long-term track record of success

Large and Growing Global Market Opportunity
Addressing a large and underpenetrated global diagnostics testing market

Customer Focused Growth Strategy
LumiraDx will drive adoption of the platform through partnerships in three core channels:
1. Physician Office/Retail/Pharmacy 2. Acute/Emergency Care 3. Global Health

Robust Pipeline of Assays
The LumiraDx platform has a robust assay pipeline that will enable the opportunity to improve care pathways and outcomes at the Point Of Care.

Transformative Technology
The LumiraDx platform technology delivers fast lab-comparable performance at the POC through a portable digitally connected system.

Proven Platform
Platform validation of several assays with blue-chip customers, including CVS, NHS, and The Gates Foundation

Proprietary Manufacturing Advantage
World-class manufacturing capabilities enable large-scale low-cost production with significant capacity levels.

lumiraDx™

A Proven Platform That Delivers

Allows for Multiple Sample Types and Test Technologies on Common Strip Architecture

Test Technologies

- Immunoassay
- Enzyme
- Molecular
- Clinical Chemistry
- Hematology
- Electrolytes / Blood Gas

Sample Types

- Fingerstick blood
- Venous blood/ Plasma/Serum
- Nasal/Nasopharyngeal Throat Swab + Saliva
- Urine



lumiraDx™

Addresses a Large and Underpenetrated POC Testing Market Opportunity

Global Diagnostics Testing Market (incl. COVID-19)



Represents a ~$79 B growth opportunity for LumiraDx's POC testing to take testing volume share

Testing Prices



POC's limited market share is due to limited menu of expensive tests. LumiraDx sees a significant opportunity to expand POC market share with broader test menu and performance similar to central laboratory with lower prices at POC.

Note: Global Diagnostics Testing Market and Testing Prices based on company estimates and exclude the mass screening market which we intend to target with our Amira System, assuming completion of development and regulatory approval.

Rapid Rollout of Platform Assays In 2021-2022 Focus on Largest Testing Needs in Community Based Care

Test	IVD Category	Market Segments	CE Mark[1]	FDA Submission[2]	TAM[3]
COVID-19 antigen	Immunoassay	Physician office, Retail/Pharmacy, Acute/Emergency Care, Global Health	Complete	Complete	~$4-$16B[4,5]
COVID-19 antigen pool	Immunoassay	Physician office, Retail/Pharmacy, Acute/Emergency Care, Global Health	Complete	H2 2021	~$2-$8B[4,5]
COVID-19 antibody	Immunoassay	Physician office, Retail/Pharmacy	Complete	Submitted	~$1-$3B
INR	Coagulation	Physician office, Retail/Pharmacy	Complete	H1 2022	~$500M
D-Dimer	Immunoassay	Physician office, Acute/Emergency Care	Complete	H2 2022	~$700M
Flu A/B + COVID-19	Immunoassay	Physician office, Retail/Pharmacy, Acute/Emergency Care	H2 2021	H2 2021	~$1.5-3B[4]
RSV + COVID-19	Immunoassay	Physician office, Retail/Pharmacy, Acute/Emergency Care	H2 2021	H2 2021	~$200-$450M[4]
CRP	Immunoassay	Physician office, Retail/Pharmacy, Global Health	H2 2021	TBC	~$300M
HbA1c	Immunoassay	Physician office, Retail/Pharmacy	H1 2022	H2 2022	~$1.3B
HS Troponin I	Immunoassay	Acute/Emergency Care	H1 2022	H2 2022	~$900M
Strep A	Molecular	Physician office, Retail/Pharmacy, Acute/Emergency Care	H2 2022	H2 2022	~$300M
TB	Molecular	Global Health	H2 2022	N/A	~$250M
Na, K	Clinical Chemistry	Physician office, Retail/Pharmacy, Acute/Emergency Care	H2 2022	H2 2022	~$150M
Hemoglobin	Hematology	Physician office, Retail/Pharmacy, Acute/Emergency Care, Global Health	H2 2022	H2 2022	~$400M
BNP / NT-proBNP	Immunoassay	Acute/Emergency Care	H2 2022	H2 2022	~$700M

(1) CE Mark timelines based on self-certification and may be impacted by IVDR
(2) Launch dates dependent on device classification and related FDA review timelines
(3) Global Total Addressable Market ("TAM"), based on our assumptions, including the (1) existing market sizes, (2) central lab market that could move to the POC, and (3) expansion of diagnostic testing
(4) COVID-19 antigen TAMs may overlap with each other (e.g., COVID-19 antigen, COVID-19 antigen pool, Flu A/B + COVID-19, RSV + COVID-19)
(5) COVID-19 antigen TAM is expected to be ~$10-$16B during 2021 and is expected to drop down to ~$4-$6B going forward. COVID-19 antigen pool TAM is expected to be ~$5-$8B during 2021 and is expected to drop down to ~$2B-$3B going forward

lumiraDx™

Amira Focused on COVID-19 Near Term, With Broader Screening and Home Testing Capabilities

Amira Test Strip and Carton

Amira Device

LumiraDx Engage App

Near Term

- $2-4 COVID-19 Antigen Test for POC and OTC use in Fall 2021

Mid-Term

- High sensitivity, connected screening for infectious diseases:
  - HIV, Malaria, Dengue

Long Term

- At-home monitoring of chronic conditions as well as OTC testing solutions

lumiraDx™

Unmet need for High Sensitivity Flu A/B + COVID-19 Combo Antigen Test

Key differential

	TRUE POC Product Needs	Quidel Sofia	BD Veritor
Technology	Next-gen technology with reduced interferences	Lateral Flow with Reader	Lateral Flow with Reader
Reference	Molecular	Molecular (COVID) Culture (Flu)	Molecular (COVID) Molecular, LF (Flu)
Intended use	**10+ DSO**	5 DSO, presumptive after 5 days	6 DSO, all negative presumptive
EUA COVID-19 PPA	**≥95% vs. RT-PCR**	95.2% (n=42 vs. RT-PCR)	86.7% (n=60 vs. RT-PCR)
EUA Flu A PPA	**≥90% vs. RT-PCR**	100% (n=70 vs. 510K Sofia and Solana) 510K data Nasal: 90.0% (n=138 vs. culture) NP: 97.1%(n=103 vs. culture)	100% (n=40 vs 510K BD Flu A/B) 510K data 82.7% (n=226 vs. RT-PCR)
EUA Flu B PPA	**≥90% vs. RT-PCR**	100% (n=15 vs. 510K Sofia and Solana) 510K data Nasal: 89.0% (n=112 vs. culture) NP: 90.0% (n=112 vs. culture)	100% (n=35 vs 510K BD Flu A/B) 510K data 80.7% (n=171 vs RT-PCR)
LOD	**SARS-CoV-2: <50 TCID50/mL** **Flu A (H3N2): <100 TCID50/mL** **Flu B: <100 TCID50/mL**	SARS-CoV-2: 91.7 TCID50/mL Flu A (H3N2): 50 TCID50/mL Flu B: 1.8 TCID50/mL	SARS-CoV-2: 2.8 x 102 TCID50/mL Flu A (H3N2): 4.11 x 104 TCID50/mL Flu B: 3.97 x 107 EID50/mL
Time to results	**<12 min**	15 min	15 min
Sample types	Nasal	Nasal, NP	Nasal

lumiraDx™

Flu A/B + COVID-19 POC Testing is Significant Near-Term Revenue Opportunity



$1.5-3B TAM

- $20-25 est market price
- Combo reimbursed at $63-73 in US vs. $43 for COVID only

45+

Countries with LumiraDx Platform globally for Flu+COVID combo testing

3,500+

Instruments placed in the US for Flu+COVID combo testing

LumiraDx has expanded COVID-19 testing into community settings such as airports, schools, cruise lines, sporting events, workplaces, and other public events.

Countries covered

Significant Worldwide Distribution

Customer Focused Growth Strategy: 3-Year Roadmap

	Physician Office / Retail / Pharmacy	Acute / Emergency Care	Global Health
Install Base	5,000+	2,000+	5,000+
Commercially Available	INR D-Dimer COVID-19 Antigen COVID-19 Antibody	D-Dimer COVID-19 Antigen COVID-19 Antibody	COVID-19 Antigen
Strategic Partners	CVS pharmacy, Boots, US Health Systems	NHS	Bill & Melinda Gates foundation
2021-2022 Launch	CRP Flu A/B + COVID-19 RSV + COVID-19 HbA1c Na, K Strep A Hemoglobin BNP / NT-proBNP	Flu A/B + COVID-19 RSV + COVID-19 HS Troponin Na, K Hemoglobin BNP / NT-proBNP	CRP Flu A/B + COVID-19 TB Hemoglobin HbA1c
3 Year Roadmap	Sexual Health Diabetes Cardiovascular disease Respiratory	Cardiac Respiratory Hospital Acquired Infection	Virology Vector Borne Disease

Note: Total instrument shipments are 15,000 with 3,000 estimated for use in COVID-19 screening applications with future testing needs to be determined

A Broad Testing Menu Will Drive Robust Testing Volumes and Attractive Unit Economics

Illustration: US Physician Office Group
Total Revenue Per Year

		YEAR 1			YEAR 2			YEAR 3		
		Test Volume	ASP	Revenue	Test Volume	ASP	Revenue	Test Volume	ASP	Revenue
Respiratory	Flu A/B	1,140	$7.50	$8,550	1,140	$7.50	$8,550	1,140	$7.50	**$8,550**
	COVID-19	1,140	$16.00	$18,240	1,140	$16.00	$18,240	1,140	$16.00	**$18,240**
	Strep A (MDX)				1,008	$14.00	$14,112	1,008	$14.00	**$14,112**
Diabetes	HbA1c				480	$5.00	$2,400	1,440	$5.00	**$7,200**
	Glucose							1,440	$3.00	**$4,320**
	Cr							720	$3.00	**$2,160**
Cardiovascular	Lipids							1,872	$6.00	**$11,232**
	Na, K				936	$4.00	$3,744	936	$3.00	**$2,808**
	ALT/AST							1,152	$4.00	**$4,608**
Sexual Health	hCG							1,152	$3.00	**$3,456**
	CT/NG (MDX)							288	$10.00	**$2,880**
Coagulation	INR				1,584	$4.00	$6,336	1,584	$4.00	**$6,336**
TOTAL		**2,280**		**$26,790**	**6,288**		**$53,382**	**13,872**		**$85,902**

Menu and pricing strategy allows for meaningful revenue/margin to LumiraDx as well as the Customer.

Note 1: Pricing is directional only
Note 2: for illustration purposes only, actuals may vary depending on market circumstances, volumes, reimbursement, customer demand or other factors

Global Commercial Footprint Poised For Growth

- **>1,500+** employees, of which **>200** are commercial employees located in **27** countries
- Direct sales operations in Western Europe, USA, Japan, Colombia, Brazil, India and Africa
- Distribution in another **>30** countries. Total reach **>90** countries
- Over time, plan to operate with a direct commercial presence in each of the largest diagnostics markets, including China, South Korea, Southeast Asia and Latin America to ensure broad access of our Platform globally



Direct (Current) **Direct (Planned)**

15K Platform Shipments Globally and Further Market Access Plans

North America
- US registered: COVID-19 Ag (EUA), COVID-19 Ab (EUA submitted)
- Canada: COVID-19 Ag submitted

Europe and Middle East
- CE Mark: COVID-19 Ag, COVID-19 Pool, COVID-19 Ab, INR, D-Dimer
- Registrations underway in ME and Russia

Asia Pacific
- Japan, Hong Kong, and Australia registered
- Registration underway in India, Indonesia, Thailand, Malaysia, Singapore, others

South America
- Brazil ANVISA: COVID-19 Ag, COVID-19 Ag Pool, COVID-19 Ab, D-Dimer, INR
- Colombia: COVID-19 Ag

Africa
- WHO PQ: COVID-19 Ag and transition to country procurement in process, currently available through EUA

● Instrument Placement Locations

lumiraDx™

Large Scale Manufacturing Infrastructure Enabling Global Growth

	Instruments	*Test Strips*
LumiraDx Platform	• Manufactured by Flextronics in Althofen, Austria	• Manufactured on a common platform using a high volume, web-based, automated process • Capacity of 28M+ test strips per month • Located in Scotland and U.S. (strips and components)
Amira System	• Manufactured in US/planned Mexico	• Manufactured in similar fashion to platform test strips • Expected capacity of up to 10M test strips per day by the fall of 2021 • Located in England

Attractive Financial Profile

2021 Revenue Update*



Q1 and Q2 estimates

H2'21 Projections

2021 Full Year
$300 - $500 million
Projected Revenue



** Q1 and Q2 Unaudited estimates*

2021 Revenue

- Year to date:
  - $170.5 million Platform sales (including instruments and consumables)
  - $7.5 million RNA Star
  - $16.0 million other

- Full Year Update:
  - Base Revenue – from current installed base
  - Revenue Opportunities largely dependent on:
    - COVID / Flu A / Flu B commercialization
    - CRP and D-Dimer commercialization
    - COVID Screening Opportunities
    - Amira commercialization



Income Statements

(000's) - IFRS Financials	**2019**	**2020**	**H1'21** *Unaudited*
Revenue	**23,142**	**139,153**	**194,094**
Gross Margin	8,820	52,947	56,434
Research & Development	86,546	107,539	59,257
Selling, marketing and administrative	37,294	46,129	64,998
Operating Loss	**(115,020)**	**(100,721)**	**(67,821)**
Net Finance Expenses	(27,630)	(150,222)	(126,582)
Tax credit / (provision)	9,541	9,946	(1,557)
Net Loss	**(133,109)**	**(240,997)**	**(195,960)**



Financial Statement Comments

- Gross Margins in H1’21 largely impacted by non-recurring expenses related to scale up and COVID dynamics with adjusted product margins in line with expectations and long term guidance
- Pro Forma adjustments include significant non-cash adjustments related to convertible debt and other IFRS accounting for debt and equity transactions.

- Cash on hand at June 30, 2021 - $245 million
- Decrease in cash on hand from March 31, 2021 due to inventory buildup and manufacturing CAPEX, largely completed

2024 Outlook and Financial Profile

- **LumiraDx Base Case Projected Revenues - $1.00 - $1.25 Billion**
  - COVID/Flu products – 15%-20% of total revenue
  - High Sensitivity Troponin – 15%-20% of total revenue
  - BNP – 5%-10% of total revenue
  - HbA1c – 5%-10% of total revenue
  - Strong mix across other Platform pipeline products
  - Amira Platform – 5%-10% of total revenue
  - Fast Lab Solutions – 5%-7% of total revenue
- **Gross Margins exceeding 65%**
  - Highly automated, scalable manufacturing drives immediately high gross margins
  - Installed manufacturing equipment flexible across full product line, high efficiency
- **R&D Spending at 10% or less of revenue by 2024 and decreasing**
  - R&D and clinical spend higher as % in near term for product pipeline
  - Opportunity to enter new lines of business in future to leverage base technology
- **Operating Margins approximately 40%**
  - LumiraDx Platform drives significant operational efficiencies for users and the Company
  - Lower operating margins in near term to scale global commercial organization

- **Taxes** – UK Patent Box tax rates apply to significant portion of long term taxable income. Long term global effective tax rate approximately 17%
- **CAPEX** – Large manufacturing capacity installed in 2020/2021. Ongoing CAPEX largely for instrument reagent rentals (<5% of revenue)

Appendix

Unmet Need for High Sensitivity Troponin POC Test

Key differential

	True POC Needs	Lab Reference Abbott Architect STAT hs-TnI	POC Example Siemens Atellica VTLi hs-cTnI	POC Example Triage True hsTnI
Intended Use	Aids diagnosis of myocardial infarction	Aids diagnosis of myocardial infarction	Aids diagnosis of myocardial infarction	Aids diagnosis of myocardial infarction
Regulatory Authorization	CE Mark, FDA 510K	CE Mark, FDA 510K	CE Mark	CE Mark
Additional Potential Claims	**30 day prognosis**	30 day prognosis (CE Mark)	N/A	N/A
Limit of Quantitation <20% CV	≤ 2.0 ng/L	≤3.2 ng/L (specification) 1.5 – 2.9 ng/L (observed)	2.1 ng/L – plasma 3.7 ng/L – WB	2.1-3.6 ng/L – Plasma 2.8 ng/L – WB
Clinical Sensitivity	**Whole blood: 2h: 90%+**	EDTA Plasma – 2-4h: 90.9%	Whole blood - 2h: 81.3%	EDTA Plasma – 2-4h: 91.9%
Reportable Range	1.0 – 1,000 ng/L	3.2 to 50,000 ng/L	2.1 ng/L (plasma)/3.7 ng/L WB to 1,250 ng/L	0.1 ng/L to 1,000 ng/L
Sample size	**15µL**	210 µL (on-board) 10 µL (manual dilution)	30-100 µL	175 µL
Sample type	Capillary WB, venous blood, plasma	Plasma & serum (LiHep, K2 & K3 EDTA)	Capillary WB, venous WB & plasma (LiHep)	Venous WB & plasma (EDTA)
Time to Result	**10 min**	18 min (time to first result)	8 min	20 min

lumiraDx™

Unmet Need for Fast, Accurate TB Test That Can Be Used at POC

Key differential

	TRUE POC Product Needs	GeneXpert MTB/RIF	Cobas MTB
Technology	qSTAR	Real time PCR	Real time PCR
Reference	Molecular (Sputum)	Culture	Culture
Sensitivity	**Oral Swab: ≥90%**	Raw Sputum & Sediment: 93.8% (n=468)	Raw Sputum: 94.9% (n=412) Sputum Sediment: 92.2% (n=437)
Specificity	**Oral Swab: ≥95%**	Raw Sputum & Sediment: 98.7% (n=628)	Raw Sputum: 98.2% (n=332) Sputum Sediment: 96.9% (n=393)
LOD (M Tuberculosis)	≤1000 CFU/mL	600 CFU/mL (raw sputum) 3,000 CFU/mL (sputum sediment)	7.6 CFU/mL (sputum/BAL sediment) 8.8 CFU/mL (raw sputum)
Time to results	**<20 minutes**	<2 hours	~8 hours
Sample types	**Oral Swab (0.7mL)**	Raw Sputum (1mL), Sputum Sediment (0.5mL)	Raw Sputum (0.4mL), Sputum Sediment or Bronchoalveolar lavage (0.2mL)

Substantial Opportunity to Grow POC Testing in the Physician Office, Retail, Urgent Care Segments



Note 1: Current Addressable Market at POC and TAM estimates include products on market and in development
Note 2: Market Sizes do not include COVID-19 testing market

lumiraDx™

Substantial Opportunity to Grow POC Testing in the Acute Care, Hospital ED Segments



Note 1: Current Addressable Market at POC and TAM estimates include products on market and in development
Note 2: Market Sizes do not include COVID-19 testing market

lumiraDx™

Substantial Opportunity to Grow POC Testing in Global Health Segment



Note 1: Current Addressable Market at POC and TAM estimates include products on market and in development
Note 2: Market Sizes do not include COVID-19 testing market

lumiraDx™

Next Gen, Microfluidic Immunofluorescence Technology Drives High Sensitivity At Point Of Care



COVID-19 Antigen — LumiraDx Platform

POC Competitive Landscape

	LumiraDx Ag	Quidel Sofia (1)	BD Veritor (1)	Abbott BinaxNOW (1)
Technology	Microfluidic Test Strip with Instrument	Lateral Flow with Reader	Lateral Flow with Reader	Lateral Flow
COV-2 Sensitivity	**97.6%**	96.7%	84.0%	84.6%
Confidence Interval	**91.6 – 99.3%**	83.3 – 99.4%	67.0 – 93.0%	76.8 – 90.6%
Intended Use Days Post Symptoms	**12**	5	5	7
Data Set	Nasal Swab – 83	Nasal Swab – 30	Nasal Swab – 31	Nasal Swab – 117
LOD	**$TCID_{50}$ per mL Direct – 32**	$TCID_{50}$ per mL Direct – 113	$TCID_{50}$ per mL Direct – 140	$TCID_{50}$ per mL Direct – 141
COV-2 Specificity	96.6%	100%	100%	98.5%
Time-to-Results	**12 Minutes**	15 Minutes	15 Minutes	15 Minutes
Sample Types	Nasal	Nasal, NP	Nasal	Nasal

Fastest, most sensitive antigen POC test currently commercially available

(1) Tests included represent some COVID-19 antigen tests that have received EUA.
Sources: Product inserts and Emergency Use Authorization documentation for such products.

High Sensitivity Up to Ct<33 Enables Fast, Accurate Detection of Infective Individuals



Source: Adapted from La Scola, B. et al. Eur J Clin Microbiol Infect Dis. 2020; 39(6):1059–1061

The Incremental Sensitivity Has Public Health Impact

- ~50% of COVID-19 patients measure Ct>25 and 30% measure Ct>30 on PCR and are potentially missed by antigen lateral flow tests[1]
- LumiraDx COVID-19 antigen test demonstrates high sensitivity at Ct<33
  - **100% sensitivity at CT<33 in clinical studies**
  - **97.6% overall positive agreement with PCR for samples collected within 12 days from symptom onset (DSO)**
  - **12 DSO is almost 2 times greater than any other antigen test**
- LumiraDx COVID-19 antigen test can detect 10-30%* of incremental cases, high coverage of all infective individuals

*Based on company estimate

(1) Ct values differ by platform, and the distribution varies by population; these are some estimates based on literature.